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Background/Aims: Autologous stem cell transplantation (ASCT) has become the treatment of choice for patients
with multiple myeloma (MM). Studies have shown that maintenance treatment with interferon-alpha is associated
with improved survival rates following ASCT. However, despite these recent advances in regimes, relapses are
inevitable; thus, the prediction of relapse following ASCT requires assessment. 
Methods: We retrospectively analyzed 39 patients who received ASCT between 2003 and 2008. All patients
received chemotherapy with vincristine, adriamycin, and dexamethasone (VAD), and ASCT was performed follow-
ing high-dose melphalan conditioning therapy. We evaluated the influence of the post-transplant day +14 (D+14)
bone marrow plasma cell percent (BMPCp) (≥ 2 vs. < 2%), international scoring system (ISS) stage (II vs. III),
response after 3 cycles of VAD therapy (complete response [CR] vs. non-CR), deletion of chromosome 13q
(del[13q]) (presence of the abnormality vs. absence), and BMPCp at diagnosis (≥ 50 vs. < 50%) on progression-
free survival (PFS) and overall survival (OS).
Results: During the median follow-up of 28.0 months, the median PFS and OS were 29.1 and 42.1 months,
respectively. By univariate analysis, ISS stage III at diagnosis, BMPCp ≥ 50% at diagnosis, CR after 3 cycles of
VAD therapy, del (13q) by fluorescence in situ hybridization, and BMPCp ≥ 2% at post-transplant D+14 were cor-
related with PFS and OS. A multivariate analysis revealed that a post-transplant D+14 BMPCp ≥ 2% (PFS, hazard
ratio [HR] = 4.426, p = 0.008; OS, HR = 3.545, p = 0.038) and CR after 3 cycles of VAD therapy (PFS, HR =
0.072, p = 0.014; OS, HR = 0.055, p = 0.015) were independent prognostic parameters.
Conclusions: Post-transplant D+14 BMPCp is a useful parameter for predicting the outcome for patients with MM
receiving ASCT. (Korean J Intern Med 2011;26:76-81)
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INTRODUCTION
Multiple myeloma (MM) is an incurable disease with a
median survival of three years after conventional
chemotherapy. High-dose chemotherapy followed by
autologous stem cell transplantation (ASCT) is currently
the standard treatment for patients with MM aged below
65 years. Several studies have shown that high-dose ASCT
is associated with an improved response rate and pro-
longed progression-free survival (PFS) and overall sur-
vival (OS) compared to conventional chemotherapy [1,2].
In a recent study, alpha-interferon maintenance treat-
ment was shown to be associated with improved survival
rates after high-dose treatment and ASCT in patients with
MM [3]. Unfortunately, despite these recent advances,Hwang IH, et al. Predictive value of post-transplant BMPCp in MM received ASCT    77
relapses are frequent; thus, the development of effective
diagnostic approaches that can anticipate the response
duration of ASCT-based strategies is required. 
Several prognostic factors following ASCT, including
cytogenetic abnormalities (e.g., the deletion of chromo-
some 13q [del(13q)]), the plasma cell labeling index
(PCLI), and the international scoring system (ISS), have
been reported to be useful parameters of patient outcome
[4-10]. Several recent studies have demonstrated an asso-
ciation between pre-transplant complete response (CR)
and outcome in MM patients receiving ASCT [11-13];
however, CR did not represent the effectiveness of the
conditioning regimen for ASCT directly. Furthermore,
recent studies have identified post- rather than pre-trans-
plant CR as an important prognostic factor [14]. 
In the present study, we therefore evaluated the prog-
nostic influence of the post-transplant day +14 (D+14)
bone marrow plasma cell percent (BMPCp) as a reflection
of the efficacy of the conditioning regimen on PFS and OS
in newly diagnosed MM patients.
METHODS
Patients
We retrospectively analyzed MM patients who were ini-
tially above ISS stage II and chemosensitive (i.e., achieved
at least a partial response) to induction therapy between
February 2003 and January 2008. Thirty-nine patients
(26 males and 13 females; median age, 57 years [range, 37
to 63]) with MM were treated with the same induction
therapy (vincristine, adriamycin, and dexamethasone
[VAD]) followed by single ASCT. All patients received
stem cell support following melphalan therapy as a condi-
tioning regimen. 
Treatment schedule 
Four, three-week cycles of induction therapy with VAD
were performed. Peripheral blood stem cell collections
(PBSCCs) were accumulated following the administration
of high-dose cyclophosphamide and mobilized with gran-
ulocyte colony-stimulating factor (G-CSF). The patients
also received 200 mg/m
2 melphalan as a conditioning reg-
imen. Autologous blood stem cells were infused on day
0 through a central venous catheter preceded by an intra-
venous injection of 50 mg of pheniramine maleate and
125 mg of methylprednisone. Post-transplant, the patients
received 5 µg/kg G-CSF subcutaneously each day from
post-transplant day +3 until engraftment. The patients
received prophylactic ciprofloxacin, itraconazole, and acy-
clovir. Following high-dose ASCT, all patients were sched-
uled to receive 2 years of maintenance therapy with inter-
feron (3 µg on 3 occasions weekly) and prednisone (50 mg
on alternate days) if the disease status did not show pro-
gression.  
Cytogenetic study
All patients underwent a bone marrow biopsy and con-
ventional cytogenetic analysis at diagnosis following
3 cycles of therapy with VAD and post-transplant D+14.
The BMPCp was determined using both aspirate smears
and histological samples. The review included an exami-
nation of each bone marrow (BM) slide to obtain an esti-
mate of cellularity and the number and proportion of plas-
ma cells (PCs) per field in histological sections. In addition,
differential counts for PCs, lymphocytes, and histiocytes
were performed on the smears. Del (13q) was identified by
interphase fluorescence in situ hybridization (FISH) of BM
samples at diagnosis as the chromosomal abnormality was
associated with a short PFS and OS in previous studies [10]. 
Response assessment of induction therapy 
A response assessment of the induction therapy was
performed after 3 cycles of therapy according to
International Myeloma Working Group criteria [15].
Briefly, CR was defined by negative immunofixation on
serum and urine, < 5% plasma cells in the BM, and the
disappearance of any soft-tissue plasmacytoma. If present
at baseline; a very good partial response (VGPR) was
defined as a reduction of ≥ 90% in the serum M-protein
level and a urine M-protein level of < 100 mg after 24
hours. A partial response (PR) was defined as a ≥ 50%
reduction in serum M protein and a reduction in the 24-
hour M-protein level by ≥ 90% or to < 200 mg, and a ≥
50% reduction in size of the soft-tissue plasmacytoma.
Patients not meeting the criteria for CR, VGPR, PR, or
progressive disease (PD) were defined as having stable
disease (SD). PD was defined as the presence of at least
one of the following conditions: an increase of ≥ 25% from
baseline in the serum or urine M-protein level with an
absolute increase of at least 0.5 g/dL and 200 mg after 24
hours, respectively. 
Statistical analysis
All statistical analyses were performed using SPSS ver-
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Whitney U test was used to compare those patients with a
BMPC of ≥ 2% on post-transplant D+14 with those show-
ing a BMPCp of < 2%. The relationship between BMPCp
after 3 cycles of VAD therapy and BMPCp at post-trans-
plant D+14 was determined by Spearman correlation
analysis. PFS was measured from the start of treatment to
the date of progression. OS was measured from the start
of treatment to the date of death or last follow-up visit.
PFS and OS were estimated using the Kaplan-Meier
method and compared with these two groups using the
log-rank test. Cox proportional hazard models were used
for univariate and multivariate analyses to evaluate the
predictive value of BMPCp at post-transplant D+14 on
PFS and OS compared to other predictive factors (e.g.,
BMPCp at diagnosis, CR after 3 cycles of induction thera-
py, del [13q] by FISH, and ISS stage III at diagnosis). 
RESULTS
The patients’ characteristics are shown in Table 1. The
median follow-up duration was 28.0 months. The median
PFS and OS were 29.1 and 42.1 months, respectively. The
ISS at diagnosis was stage II (n = 25) or III (n = 14). The
types of M protein were IgG (n = 23), IgA (n = 12), and
others (n = 4). The median BMPCp at diagnosis was
43.0% (range, 11 to 57); chromosomal abnormalities were
found by conventional cytogenetic analysis in 15 patients.
Del (13q) was detected by FISH in 8 patients. Following
induction therapy with VAD, 12 patients achieved a CR.
The infused mean CD34+ stem cell dose was 4.1 × 10
6/kg
(range, 2.1 to 6.1), while the median BMPCp at post-trans-
plant D+14 was 0.7% (range, 0 to 4.0). An analysis of the
different cut-off levels between the 25 and 75% quartiles
(range, 0.2 to 2.2) using the log-rank test determined that
a BMPCp of 2% was the cut-off point yielding the greatest
difference in PFS and OS; thus, this value was used as the
cut-off level in our statistical analyses. 
Comparison of patient characteristics according
to BMPCp at post-transplant D+14
The baseline characteristics (age, sex, type, chromoso-
mal abnormality, BMPCp at diagnosis, and stage) were
compatible between the BMPCp ≥ 2% at post-transplant
D+14 and BMPCp < 2% groups (Table 1). The response
following 3 cycles of VAD therapy was not different
between the two BMPCp groups. 
Table 1. Baseline patient characteristics 
Characteristics Total BMPCp  ≥ 2%  BMPCp < 2%  p value
at post-transplant  at post-transplant
D+14 D+14
Age, yr  57 (37-63) 52.5 (37-60) 57 (38-63) 0.210
Male/Female 26/13 7/5 19/8 0.558
Type 
IgG  23 (59.0) 7 (18.0) 16 (41.0) 0.954
IgA  12 (30.8) 3 (7.7) 9 (23.1) 0.685
Others  4 (10.2) 2 (5.1) 2 (5.1) 0.663
BMPCp at diagnosis, %  43.0 (11-57) 47.5 (11-57) 38.0 (23-56) 0.599
Cytogenetic abnormality  15 (38.5) 5 (12.8) 10 (25.7) 0.753
Del (13q) by FISH  8 (20.5) 3 (7.7) 5 (12.8)
Response after 3 cycle of VAD therapy  0.685
CR  12 (30.8) 3 (7.7) 9 (23.1)
Non-CR  27 (69.2) 9 (23.1) 18 (46.2)
ISS at diagnosis  0.327
II  25 (64.1) 6 (15.4) 19 (48.7)
III  14 (35.9) 6 (15.4) 8 (20.5)
CD34+ cell dose, x 10
6/kg, mean (range)  4.1 (2.1-6.1) 4.1 (2.1-5.4) 4.0 (2.6-6.1) 0.391
Values are presented as number (%) or median (range) unless otherwise indicated.
BMPCp, bone marrow plasma cell percent; FISH, fluorescence in situ hybridization; VAD, vincristine, adriamycin, and dexamethasone; CR, com-
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Correlation between BMPCp after 3 cycles of VAD
therapy and BMPCp on post-transplant D+14
To estimate whether induction therapy with VAD influ-
enced the post-transplant BMPCp, the correlation
between BMPCps after 3 cycles of VAD therapy and post-
transplant D+14 was estimated by Spearman correlation
analysis. In the analysis, BMPCps between and above the
two groups did not correlate (r = -0.071, p= 0.669, Fig. 1).
Impact of BMPCp at post-transplant D+14 on PFS
and OS
The PFS and OS according to BMPCp at post-transplant
D+14 are shown in Fig. 2A and 2B, respectively. PFS in
the BMPCp ≥ 2% group at post-transplant D+14 was sig-
nificantly shorter than in the < 2% group (p = 0.001, Fig.
2A). Similarly, OS in the BMPC ≥ 2% group at post-trans-
plant D+14 was significantly shorter than in the BMPCp <
2% group (p= 0.001, Fig. 2B). 
A univariate analysis revealed that BMPCp ≥2% at post-
transplant D+14 was associated with a reduced PFS and
OS (PFS, hazard ratio [HR] = 3.957, 95% confidence
interval [CI] = 1.633-9.588, p = 0.002; OS, HR = 4.048,
95% CI = 1.622-10.103, p = 0.003, Table 2). Other factors
(ISS stage III at diagnosis, ≥ 50% BMPCp at diagnosis, no
CR after 3 cycles of VAD therapy, and del [13q] by FISH)
were also correlated with the shorter PFS and OS (Table
2). A multivariate analysis using Cox proportional hazard
models confirmed that a BMPCp ≥ 2% at post-transplant
D+14 and CR following 3 cycles of VAD therapy repre-
sented independent prognostic factors for PFS and OS
(Table 3).
Figure 1. Correlation between BMPCp after 3 cycles of VAD and
BMPCp at post-transplant D+14. The BMPCp following 3 cycles of
VAD therapy did not correlate with the BMPCp at post-transplant
D+14 (r = -0.071, p = 0.669). BMPCp, bone marrow plasma cell
percent; VAD, vincristine, adriamycin, and dexamethasone.
Figure 2. Influence of the BMPCp at post-transplant D+14 on (A) PFS and (B) OS. The patient group with a BMPCp ≥ 2% at post-trans-
plant D+14 was associated with reductions in PFS and OS compared to the group with a BMPCp < 2% at post-transplant D+14 (PFS, p =
0.001; OS, p= 0.001). BMPCp, bone marrow plasma cell percent; PFS, progression-free survival; OS, overall survival.
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DISCUSSION
CR is defined by European Group for Blood and
Marrow Transplant/International Myeloma Working
Group uniform response criteria as the absence of serum
and urine monoclonal M proteins by immunofixation
(IFE) and < 5% PCs in the BM [15]. Several recent studies
have shown that the pre-transplant CR is not associated
with a better outcome in MM patients [11-13]. However,
these studies did not interpret the importance of BMPC
counts. Recent studies have demonstrated that the sur-
vival of patients who achieved a true CR (negative serum
and urine IFE and < 5% BMPCs) was significantly longer
than CR patients with ≥ 5% BMPCs [16]. This would be
important to prevent the inclusion of a significant propor-
tion of false-positive CR cases if the BM examination was
removed. It is therefore suggested that the BMPC count is
crucial for the prediction of survival in MM patients. 
The present study showed that the post-transplant
BMPCp was not associated with the BMPCp or response
following 3 cycles of induction therapy. The BMPCp ≥ 2%
at post-transplant D+14 group correlated with a poor sur-
vival rate compared to the BMPCp < 2% group. The base-
line characteristics, including the response after 3 cycles of
VAD therapy, did not differ between the two groups.
Furthermore, the BMPCp after 3 cycles of VAD therapy
did not correlate with the post-transplant BMPCp. This
result demonstrates that the efficacy of the conditioning
regimen rather than the impact of induction therapy influ-
ences the post-transplant BMPCp. Although in previous
studies the pre-transplant CR was not equivalent to the
CR after 3 cycles of VAD therapy, the present study sug-
gests that the post-transplant BMPCp represents a novel
prognostic parameter irrespective of the pre-transplant
disease status. Recent studies showing contrasting results
have been reported, whereby the post-transplant CR
rather than pre-transplant CR was associated with sur-
vival in newly diagnosed MM patients [14]. These studies
suggest that achieving a response by high-dose ASCT
could be an important prognostic factor of the outcome.
Thus, the importance of the BMPCp could be understood
in the context of post-transplant CR in these studies. 
Other studies have revealed several prognostic factors
such as cytogenetics, the plasma cell labeling index, ISS,
and pre- and post-transplant CR status in ASCT, which
may be useful in planning individualized treatment
regimes [2-14]. Similarly, the present study shows that ISS
Table 2. Univariate analysis of prognostic factors for survival after ASCT
Prognostic factor Progression-free survival Overall survival
HR (95% CI) p value HR (95% CI) p value
ISS stage III at diagnosis 4.437 (1.751-11.244) 0.002 4.808 (1.826-12.663) 0.001
BMPCp at diagnosis ≥ 50% 3.890 (1.406-10.763) 0.009 5.254 (1.759-15.689) 0.003
CR after 3 cycles of VAD therapy 0.081 (0.011-0.613) 0.015 0.064 (0.008-0.527) 0.011
Del (13q) by FISH 4.059 (1.380-11.937) 0.011 4.579 (1.474-14.225) 0.009
BMPCp ≥ 2% at post-transplant D+14 3.957 (1.633-9.588) 0.002 4.048 (1.622-10.103) 0.003
ASCT, autologous stem cell transplantation; HR, hazard ratio; CI, confidence interval; ISS, international staging system; BMPCp, bone marrow
plasma cell percent; CR, complete response; VAD, vincristine, adriamycin, and dexamethasone; FISH, fluorescence in situ hybridization.
Table 3. Multivariate analysis of prognostic factors for survival after ASCT
Prognostic factor Progression-free survival Overall survival
HR (95% CI) p value HR (95% CI) p value
ISS stage III at diagnosis 2.224 (0.789-6.268) 0.131 2.231 (0.750-6.635) 0.149
BMPCp at diagnosis ≥ 50% 0.997 (0.287-3.468) 0.996 1.377 (0.352-5.377) 0.646
CR after 3 cycles of VAD therapy 0.072 (0.009-0.583) 0.014 0.055 (0.005-0.562) 0.015
Del (13q) by FISH 3.171 (0.936-10.749) 0.064 2.557 (0.787-8.312) 0.119
BMPCp ≥ 2% at post-transplant D+14 4.426 (1.470-13.327) 0.008 3.545 (1.071-11.727) 0.038
ASCT, autologous stem cell transplantation; HR, hazard ratio; CI, confidence interval; ISS, international staging system; BMPCp, bone
marrow plasma cell percent; CR, complete response; VAD, vincristine, adriamycin, and dexamethasone; FISH, fluorescence in situ
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stage III, a BMPCp ≥50% at diagnosis, CR after 3 cycles of
VAD therapy, and del (13q) as well as a BMPCp ≥ 2% at
post-transplant D+14 were associated with PFS and OS in
a univariate analysis. However, our multivariate analysis
revealed that only CR following 3 cycles of VAD therapy
and BMPCp ≥ 2% at post-transplant D+14 were indepen-
dent factors predicting PFS and OS. This early diagnostic
approach at engraftment may have an important role in
the prediction of outcome in ASCT.
Our data demonstrate that early detection of the resid-
ual myeloma burden by BM examination post-transplan-
tation is an important factor in predicting the outcome for
MM patients receiving single ASCT. A higher BMPCp at
post-transplant D+14 may denote the necessity of the con-
ditioning strategy, including high-intensity or novel
agents, tandem ASCT, or more intensive maintenance
therapy. Although this study investigated only a small
number of patients and was retrospective in design, we
identified a novel parameter for the early detection of the
residual myeloma burden in ASCT. A well-designed
prospective study that includes an examination of the BM
on post-transplant D+14 is needed to provide further
information regarding these observations.
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